Avenue Therapeutics (ATXI) Registration Filing summary

Company overview and business model

• Focuses on developing and commercializing therapies for neurologic diseases, including AJ201 for spinal and bulbar muscular atrophy, IV tramadol for post-operative acute pain, and BAER-101 for epilepsy and panic disorders.

• AJ201 is in a Phase 1b/2a clinical trial, with top-line data expected around year-end 2024.

• IV tramadol is advancing toward a Phase 3 safety study, pending financing.

• BAER-101, acquired through Baergic, has shown promising preclinical results in epilepsy models.

• Operates as a majority-controlled subsidiary of Fortress, with Baergic as its sole subsidiary.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates is approximately $4.7 million as of December 3, 2024.

• The company is classified as a smaller reporting company and has incurred substantial operating losses since inception, with ongoing doubts about its ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes and working capital, including advancing product candidates toward FDA approval and milestone payments to licensors.

• Management has broad discretion over allocation of proceeds, with no current plans for acquisitions.